Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology (patents filed) enabling GMP compliant manufacture of antigen-specific T cells and employs a team of production specialists led by Rainer Knaus, PhD and Katy Newton, PhD. The in-house trial management team, led by Karen Hodgkin, has unique expertise in planning and executing cell therapy trials.